Assessment of Personalized Follow-up in Prevention of Type 2 Diabetes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRamsay Générale de Santé

About this trial

In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis.

The Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life.

From a medico-economic point of view, chronic pathologies (including diabetes) account for 60% of insurance expenditure illness even though they concern 35% of insured persons, i.e. 20 million patients. The average annual repayment of a type 2 diabetic patient is 4890 euros.

This study is part of this context as the starting point a reflection on a different, coordinated management, to know a preventive rather than a curative approach.

Eligibility criteria

Qualifiers

Patient, male or female, over the age of 18

Patient with a FINDRISC score ≥10 points

Beneficiary of a French health insurance system

Patient having been informed and having given their consent free, enlightened and written

Disqualifiers

Patient over 75 years old

Patient already diagnosed with type 2 diabetes

Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant.

Patient participating in another research

Trial design

Treatments tested in this trial

  • Study nurse intervention

Treatment groups

230 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ramsay Générale de Santé

Lead sponsor

European Clinical Trial Experts Network

Collaborator